CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype
- PMID: 27659530
- PMCID: PMC5346671
- DOI: 10.18632/oncotarget.12168
CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype
Abstract
The chemotherapeutic agent 5-Fluorouracil (5-FU) is the most commonly used drug for patients with advanced colon cancer. However, development of resistance to 5-FU is inevitable in almost all patients. The mechanism by which colon cancer develops 5-FU resistance is still unclear. One recently proposed theory is that cancer stem-like cells underlie colon cancer 5-FU resistance, but the phenotypes of 5-FU-resistant colon cancer stem cells are still controversial. We report here that 5-FU treatment selectively enriches a subset of CD133+ colon cancer cells in vitro. 5-FU chemotherapy also increases CD133+ tumor cells in human colon cancer patients. However, sorted CD133+ colon cancer cells exhibit no increased resistance to 5-FU, and CD133 levels exhibit no correlation with colon cancer patient survival or cancer recurrence. Genome-wide analysis of gene expression between sorted CD133+ colon cancer cells and 5-FU-selected colon cancer cells identifies 207 differentially expressed genes. CD24 is one of the genes whose expression level is lower in the CD133+ and 5-FU-resistant colon cancer cells as compared to CD133+ and 5-FU-sensitive colon cancer cells. Consequently, CD133+CD24lo cells exhibit decreased sensitivity to 5-FU. Therefore, we determine that CD133+CD24lo phenotype defines 5-FU-resistant human colon cancer stem cell-like cells.
Keywords: 5-Fluorouracil; CD133; CD24; colon cancer stem cells.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g007.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5346671/bin/oncotarget-07-78698-g008.gif)
Similar articles
-
Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer.Anticancer Agents Med Chem. 2021;21(17):2297-2303. doi: 10.2174/1871520621666210129094354. Anticancer Agents Med Chem. 2021. PMID: 33511942 Review.
-
Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.Nutrients. 2018 Jul 12;10(7):888. doi: 10.3390/nu10070888. Nutrients. 2018. PMID: 30002278 Free PMC article.
-
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.Tumour Biol. 2016 Sep;37(9):12889-12896. doi: 10.1007/s13277-016-5209-5. Epub 2016 Jul 23. Tumour Biol. 2016. PMID: 27449042
-
5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells.Chin J Cancer. 2010 Sep;29(9):810-5. doi: 10.5732/cjc.010.10134. Chin J Cancer. 2010. PMID: 20800023
-
Colon cancer stem cells: promise of targeted therapy.Gastroenterology. 2010 Jun;138(6):2151-62. doi: 10.1053/j.gastro.2009.12.063. Gastroenterology. 2010. PMID: 20420952 Review.
Cited by
-
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.Br J Cancer. 2024 May;130(8):1402-1413. doi: 10.1038/s41416-024-02649-z. Epub 2024 Mar 11. Br J Cancer. 2024. PMID: 38467828 Free PMC article.
-
Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets.Int J Mol Sci. 2023 Jun 30;24(13):10910. doi: 10.3390/ijms241310910. Int J Mol Sci. 2023. PMID: 37446085 Free PMC article. Review.
-
The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal-like breast cancer cells.FEBS Open Bio. 2023 Feb;13(2):352-362. doi: 10.1002/2211-5463.13547. Epub 2023 Jan 16. FEBS Open Bio. 2023. PMID: 36602390 Free PMC article.
-
A "conversion-deterioration-double mutation" theory for the evolution and progression of colorectal cancer.Cancer Med. 2022 Jul;11(13):2601-2611. doi: 10.1002/cam4.4637. Epub 2022 Mar 13. Cancer Med. 2022. PMID: 35285179 Free PMC article. Review.
-
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer.Cancers (Basel). 2022 Mar 7;14(5):1357. doi: 10.3390/cancers14051357. Cancers (Basel). 2022. PMID: 35267665 Free PMC article.
References
-
- Ardalan B, Subbarayan PR, Ramos Y, Gonzalez M, Fernandez A, Mezentsev D, Reis I, Duncan R, Podolsky L, Lee K, Lima M, Ganjei-Azar P. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16:3019–3027. - PubMed
-
- Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–1618. - PubMed
-
- Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338. - PubMed
-
- Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275–292. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials